Anzeige
Mehr »
Freitag, 04.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DWYX | ISIN: US19188J4094 | Ticker-Symbol: 8CC
Stuttgart
04.07.25 | 07:32
1,250 Euro
-0,79 % -0,010
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
COCRYSTAL PHARMA INC Chart 1 Jahr
5-Tage-Chart
COCRYSTAL PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2401,36012:49
1,2401,36011:37

Aktuelle News zur COCRYSTAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiCocrystal Pharma, Inc. - 8-K, Current Report1
20.06.H.C. Wainwright lowers Cocrystal Pharma stock price target on dilution1
20.06.H.C. Wainwright senkt Kursziel für Cocrystal Pharma wegen Verwässerung1
COCRYSTAL Aktie jetzt für 0€ handeln
18.06.Cocrystal Pharma, Inc. - 8-K, Current Report1
05.06.Cocrystal Pharma, Inc. - 8-K, Current Report1
29.05.Cocrystal Pharma, Inc. - 8-K, Current Report1
29.05.Cocrystal's flu drug shows promise against H5N1 strain1
15.05.Cocrystal Pharma, Inc. - 8-K, Current Report1
15.05.Cocrystal Pharma GAAP EPS of -$0.232
15.05.Cocrystal Pharma, Inc. - 10-Q, Quarterly Report4
24.04.Cocrystal Pharma, Inc.: Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants192Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025Cocrystal Pharma's pan-viral...
► Artikel lesen
23.04.Cocrystal Pharma, Inc. - 8-K, Current Report2
08.04.Cocrystal Pharma, Inc. - 8-K, Current Report2
31.03.Cocrystal Pharma, Inc. - 10-K, Annual Report1
31.03.Cocrystal Pharma, Inc. - 8-K, Current Report2
31.03.Cocrystal Pharma GAAP EPS of -$1.72 1
08.01.Cocrystal Pharma, Inc. - 8-K, Current Report5
31.12.24Cocrystal Pharma, Inc.: Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344203Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuationsEnrollment to be extended due to low influenza infection among challenged...
► Artikel lesen
15.08.24Cocrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event457NEW YORK, NY / ACCESSWIRE / August 15, 2024 / CoCrystal Pharma (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication...
► Artikel lesen
18.07.24Cocrystal Pharma, Inc.: Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor202BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company") today reported favorable safety and tolerability results from the single-ascending...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1